Evidence map›Paper›PMID 36737828›Full record

ArticleStem cell research & therapy2023

Acceptability of neural stem cell therapy for cerebral palsy: survey of the Australian cerebral palsy community.

Madeleine J Smith, Megan Finch-Edmondson, Suzanne L Miller, Annabel Webb, Michael C Fahey, Graham Jenkin, Madison Claire Badawy Paton, Courtney A McDonald

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Consumer Priorities for Upper-Extremity Outcome Assessments.Archives of rehabilitation research and clinical translation · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Madeleine J SmithThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Megan Finch-EdmondsonCerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Suzanne L MillerThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Annabel WebbCerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Michael C FaheyDepartment of Paediatrics, Monash University, Clayton, VIC, Australia.
Graham JenkinThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Madison Claire Badawy Paton *Cerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. Madison.paton@cerebralpalsy.org.au.
Courtney A McDonald *The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Cerebral Palsy Alliance · AUHudson Institute of Medical Research · AUMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeural stem cells (NSCs) have the potential to engraft and replace damaged brain tissue, repairing the damaged neonatal brain that causes cerebral palsy (CP). There are procedures that could increase engraftment of NSCs and may be critical for efficacy, but hold notable risks. Before clinical trials progress, it is important to engage with the CP community to understand their opinions. The aim of this study was to determine the acceptability of NSC therapy for CP in the CP community.

methodsAustralian residents with CP and parents/carers of those with CP completed a questionnaire to determine their willingness to use NSCs from three sources (fetal, embryonic and induced pluripotent stem cells) and their willingness to undergo accompanying procedures (neurosurgery, immunosuppression) that carry potential risks. To further explore their views, participants also answered free text questions about their ethical concerns regarding the source of NSCs and their perceptions of meaningful outcomes following NSC treatment.

resultsIn total, 232 responses were analyzed. Participants were willing to use NSCs from all three cell sources and were willing to undergo NSC therapy despite the need for neurosurgery and immunosuppression. Participants identified a range of outcome domains considered important following NSC treatment including gross motor function, quality of life, independence and cognitive function.

conclusionsHypothetical NSC therapy was acceptable to the Australian CP community. This study has identified important findings from the CP community which can be used to inform future NSC research, including the design of clinical trials which may help to increase recruitment, compliance and participant satisfaction.

Indexed as

Cerebral PalsyNeural Stem CellsAustraliaCell DifferentiationHumansInfant, NewbornQuality of LifeSurveys and QuestionnairesBrain injuryCell therapyCerebral palsyNeurosurgeryPediatric neurologyStakeholder engagement

Identifiers

PMID36737828
PMCPMC9898914
OpenAlexW4319078233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.